Jeena Sikho Lifecare Limited will participate in an investor and analyst meet scheduled for June 12, 2026. The interaction, organized by Choice Institutional Equities under their InsightX Virtual Forum, aims to engage with the investment community. Senior management, including Managing Director Manish Grover, will represent the company during the virtual session.

The meeting is scheduled to commence at 10:00 A.M. (IST) and will be conducted via a virtual group meeting format. The disclosure was made in compliance with Regulation 30 read with Para A of Part A of Schedule III of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Participation Details

The company has confirmed that the schedule remains subject to change due to exigencies on the part of the investors, analysts, or the company. It was explicitly stated that no unpublished price sensitive information pertaining to the company will be shared during these interactions.

The following representatives from Jeena Sikho Lifecare are scheduled to attend:

The event details have been made available on the company's official website.

Jeena Sikho Lifecare Limited reported a robust financial performance for the financial year ended March 31, 2026, with net profit after tax surging 177% year-on-year to ₹222 crore. Revenue from operations increased 71% to ₹801 crore, driven by strong growth in its Ayurvedic Healthcare Services and Products segments. The company’s EBITDA for FY26 stood at ₹349 crore, reflecting a 149% increase and an EBITDA margin expansion of 1,360 basis points to 44%. Management targets increasing operational beds to 3,000 within the next 3 to 4 months and aims for 7,000 to 10,000 beds in the next 3 to 5 years.

Annual Financial Performance

The company’s standalone net profit for FY26 rose to ₹222 crore from ₹80 crore in the previous year. Total income reached ₹810 crore, up from ₹476 crore in FY25. The board has recommended a final dividend of ₹4.50 per equity share for the financial year, subject to shareholder approval.

Q4 Performance Highlights

For the quarter ended March 31, 2026, net profit increased 79% to ₹45.35 crore from ₹25.34 crore in the corresponding period of the previous year. Revenue for Q4 FY26 climbed to ₹216 crore from ₹139 crore in Q4 FY25. Earnings per share (EPS) for the quarter stood at ₹3.65 on a basic basis, compared to ₹2.04 in the same period last year. The company noted that Q4 results were impacted by one-time provisions of approximately ₹19 crore, primarily related to lease adjustments, employee benefits, and ECL provisions.

Operational Expansion

The company continued its expansion, increasing total bed capacity to 2,861 beds, with 2,300 beds currently operational. Management targets increasing operational beds to 3,000 within the next 3 to 4 months and aims for 7,000 to 10,000 beds in the next 3 to 5 years. For FY26, IPD volumes grew by 65% to 40,450, while OPD volumes grew 69% to reach over 6 lakh patients. The Ayurveda Healthcare Products business contributed ₹416 crore, representing 52% of total revenue. The statutory auditors, M/s Walker Chandiok & Co LLP, issued an unmodified opinion on the results. The submission of the transcript was made pursuant to Regulations 30 and 46 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0J5801029/cbca600691764314.pdf